Anti-Human LAG3 Recombinant Nanobody (SAA2195) (HB613013)

Name: Anti-Human LAG3 Recombinant Nanobody (SAA2195)
Brand: abinScience
SKU: HB613013
Price: 126 USD
Availability: InStock

Datasheet Share product Copy info

Price(USD):

Spec:

20ug
50ug
100ug
1mg

Number:

Get quote

Overview
Images
References
Datasheet
SDS

Overview

Catalog No.

HB613013

Description

Anti-Human LAG3 Nanobody (SAA2195) [SAA2195] (HB613013) is a alpaca monoclonal antibody detecting LAG3 in ELISA. Suitable for Human.

Species reactivity

Human

Applications

ELISA

Host species

Alpaca

Isotype

VHH-8His-Cys-tag

Clone ID

SAA2195

Clonality

Monoclonal

Target

FDC, LAG3, Lymphocyte activation gene 3 protein, CD223, sLAG-3, LAG-3

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P18627

Form

Liquid

Storage buffer

0.01M PBS pH 7.4

Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Product Usage Information

Application	Dilution
ELISA	1:2000-1:20000

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Background

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648

2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082

3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750

4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185

5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966

6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841

7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469

8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152

10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708

Note

For research use only.

Images

SDS-PAGE

SDS-PAGE for Anti-Human LAG3 Nanobody (SAA2195)

References

Datasheet

Anti-Human LAG3 Recombinant Nanobody (SAA2195).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Recombinant Proteins

Antibodies

Assay Kits

Anti-Human LAG3 Recombinant Nanobody (SAA2195) (HB613013)

Overview

Images

References

Datasheet

SDS

Quick access

Contact Us